Oncotelic Therapeutics announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation will highlight findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics, underscoring the importance of tissue-level drug distribution in determining toxicity profiles.
The research supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. More information about the company's developments can be found at https://ibn.fm/kZzE3.
Oncotelic, which was formed in 1988 and has undergone several name changes including from Mateon Therapeutics to its current name in November 2020, is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. The company has rare pediatric designation for Diffuse Intrinsic Pontine Glioma through OT-101 via its 45% joint venture GMP Bio, melanoma through CA4P and its wholly owned subsidiary Sapu, and Acute Myeloid Leukemia through OXi 4503.
Beyond its oncology focus, Oncotelic has expanded its portfolio through strategic acquisitions. The company acquired PointR Data Inc. in November 2019 to build an AI-driven biotechnology company and acquired AL-101 during the fourth quarter of 2021 for the intranasal delivery of apomorphine. AL-101 is being developed for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder, conditions affecting large patient populations with significant unmet treatment needs.
The latest news and updates relating to Oncotelic are available in the company's newsroom at https://ibn.fm/OTLC. The presentation at SOT 2026 represents a significant step in advancing understanding of drug toxicity at the tissue level, which could lead to more targeted and effective cancer treatments with reduced side effects for patients.
